Micreos secures EUR32 million for its endolysin-based platform as sustainable alternative to antibiotics
The Hague, The Netherlands (ots/PRNewswire) - Dutch biotechnology company Micreos announced it has secured another EUR32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical ...
plus